Literature DB >> 7449405

Hemodynamic and oxygen transport effects of a perfluorochemical blood substitute, fluosol-DA (20%).

K K Tremper, R Lapin, E Levine, A Friedman, W C Shoemaker.   

Abstract

Cardiorespiratory measurements were made in a severely anemic patient (hemoglobin concentration of 3.5 g/dl) who was preoperatively given the perfluorochemical blood substitute (Fluosol-DA, 20%). Hemodynamic and oxygen transport variables were monitored, including arterial and mixed venous oxygen content (CaO2 and CVO2) before, during, and after infusion of 1000 ml of Fluosol as well as throughout the intraoperative period. Blood samples revealed a maximum of 2.7% of the perfluorochemical. The CaO2 increased 37% above the CaO2 calculated without Fluosol; i.e., 5.8 +/- 0.1 to 8.1 +/- 0.6 ml/dl, p < 0.01. The cardiac index (CI) decreased from 7.2 +/- 0.2 to 5.9 +/- 0.8 L/min . M2 and the left ventricular stroke work decreased from 67 +/- 6 to 58 +/- 13 g . M/M2, while the oxygen delivery increased, and the total body oxygen consumption (VO2) remained essentially unchanged.l Intraoperatively, 27% of the O2 delivery and 51% of the VO2 were transported by Fluosol. No adverse effects of the fluosol were noted.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7449405     DOI: 10.1097/00003246-198012000-00009

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  7 in total

1.  Surgery in Jehovah's Witnesses.

Authors:  D H Wong; L C Jenkins
Journal:  Can J Anaesth       Date:  1989-09       Impact factor: 5.063

2.  Water distribution and oxygen delivery.

Authors:  W C Shoemaker
Journal:  West J Med       Date:  1985-08

Review 3.  Adverse reactions to plasma volume expanders.

Authors:  M M Fisher; P W Brady
Journal:  Drug Saf       Date:  1990 Mar-Apr       Impact factor: 5.606

Review 4.  Personalized nanomedicine advancements for stem cell tracking.

Authors:  Miroslaw Janowski; Jeff W M Bulte; Piotr Walczak
Journal:  Adv Drug Deliv Rev       Date:  2012-07-20       Impact factor: 15.470

Review 5.  Current status of erythrocyte substitutes.

Authors:  G P Biro
Journal:  Can Med Assoc J       Date:  1983-08-01       Impact factor: 8.262

6.  Clinical studies of a perfluorochemical whole blood substitute (Fluosol-DA) Summary of 186 cases.

Authors:  T Mitsuno; H Ohyanagi; R Naito
Journal:  Ann Surg       Date:  1982-01       Impact factor: 12.969

Review 7.  Nanomedicines: A Potential Treatment for Blood Disorder Diseases.

Authors:  Nan Zhang; Ming-Yuan Wei; Qiang Ma
Journal:  Front Bioeng Biotechnol       Date:  2019-11-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.